BioDelivery Sciences Intl licenses BEMA buprenorphine to Endo Pharma for mild to severe Chronic Pain - 12-Jan-2012
BioDelivery Sciences International (BDSI) has licensed the world rights of BEMA buprenorphine to Endo Pharmaceuticals. BEMA buprenorphine is a treatment for moderate to severe chronic pain which blends the opioid analgesic buprenorphine with the BioErodible MucoAdhesive (BEMA) drug delivery technology. A bioerodible polymer film about the size of a fingertip attaches to the inner lining of the cheek. The film then rapidly delivers its drug dose through the mucous membranes of the inner cheek, and completely dissolves in 15 to 30 minutes. The dug failed a Phase III trial recently but BDSI are proceeding with its development with a new nine month trial.
Related News
FDA approves new product labelling for OxyContin Controlled Release(Purdue Pharma) for Pain Management
Moxduo (QRx Pharma) resubmitted to the FDA for approval for Pain control
Phase III results for ALO-02 (Pfizer) for moderate to severe Pain
FDA approves Opana ER from Endo Pharma for Moderate to Severe Pain
FDA approves Nymalize (Arbor Pharmaceuticals) for Sub Arachnoid Haemorrhage
CE Mark granted for Architectt HbA1c test to diagnose Diabetes
Enzastaurin (Eli Lilly) fails Phase III trial for B Cell Lymphoma
FDA approves Ilaris (Novartis) for treatment of Systemic Juvenile Idiopathic Arthritis
Related Pain Management Information
Pain Management Clinical Guidelines
Early management of persistent non-specific low back pain
NICETherapeutic endoscopic division of epidural adhesions
NICEPain Management Clinical Trials
Craniosacral Therapy to Treat Chronic Low Back Pain
Clinicaltrials.gov 24 March 2013Efficacy Study of Cognitive Behavioural Treatment With Support on Communication and Information Technologies for the Management of Chronic Low Back Pain (POETS)
Clinicaltrials.gov 27 February 2013Pain Management Medical Journal Abstracts
The role of circulating sex hormones in menstrual cycle dependent modulation of pain-related brain activation
Pain 04 January 2013The pattern and time course of somatosensory changes in the human UVB sunburn model reveal the presence of peripheral and central sensitization
Pain 04 January 2013Pain Management Medical Apps
Pain Scale
Free
Doctot Pain
£3.99
Related Pain Management Drugs
- OSMANIL 75MCG/HR TRANSDERMAL PATCHES
- ZAMADOL INJECTION
- MIGRIL
- CODIPAR 15MG/500MG EFFERVESCENT TABLETS
- TORADOL INJECTION
- TEMGESIC
- EFFENTORA 100, 200, 400, 600 AND 800 MICROGRAMS BUCCAL TABLETS
- TRAMAKE
- MAXALT
- OXYCONTIN TABLETS
- FROBEN TABLETS
- MAXITRAM SR
- ABSTRAL SUBLINGUAL TABLETS
- PALFIUM
- VERSATIS 5% MEDICATED PLASTER
- ANADIN ULTRA DOUBLE STRENGTH 400MG CAPSULES/ANADIN LIQUIFAST 400MG CAPSULES
- ZAMADOL 24HR 150 (200/300/400)MG TABLETS
- PETHIDINE
- MIGRAMAX
- TILODOL SR 100 MG PROLONGED-RELEASE TABLETS
- TRAMADOL
- MST CONTINUS SUSPENSIONS 20, 30, 60, 100 AND 200 MG
- ZYDOL SOLUTION FOR INJECTION
- TRAMACET 37.5 MG/ 325 MG FILM-COATED TABLETS
- TYLEX
- ZYDOL 50 MG CAPSULES
- REMEDEINE
- CODEINE PHOSPHATE TABLETS 15MG
- ZYDOL SR TABS 100MG
- DROMADOL XL
- MEPTID INJECTION
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION AND OXYNORM CONCENTRATE 10 MG/ML ORAL SOLUTION
- MIGRALEVE
- MEDINOL PAEDIATRIC
- ALMOGRAN 12.5 MG FILM-COATED TABLET
- DOMPERAMOL
- ASPAV
- JUNIOR PARAPAED PARACETAMOL SUSPENSION 120MG/5ML
- PALLADONE CAPSULES
- ACUPAN
- XEFO
- NARAMIG (MIGRAINE)
- CAFERGOT
- QUTENZA 179MG CUTANEOUS PATCH
- DICLOFENAC SODIUM 50MG TABLETS
- PANADOL ACTIFAST
- MATRIFEN
- MORPHINE SULPHATE INJECTION
- MST CONTINUS TABLETS 5 MG, 10 MG, 15 MG, 30 MG, 60 MG, 100 MG, 200 MG
- MORAXEN
- ANADIN IBUPROFEN
- MEFENAMIC ACID (GENERIC)
- MORCAP SR
- DISPRIN DIRECT
- CODEINE PHOSPHATE TABLETS 30MG
- NOBLIGAN TABLETS
- SOLPADOL
- ZAMADOL MELT 50 MG TABLETS
- ORAMORPH
- TILODOL SR 200 MG PROLONGED-RELEASE TABLETS
- MIDRID
- ZERIDAME SR PROLONGED RELEASE TABLETS
- TRANSTEC TRANSDERMAL PATCH
- ACTIQ
- DIAMORPHINE HYDROCHLORIDE INJECTION BP 5MG
- OXYNORM 10 MG/ML SOLUTION FOR INJECTION OR INFUSION
- ZYDOL 50 MG SOLUBLE TABLETS
- PALLADONE SR CAPSULES
- IMIGRAN RECOVERY
- ZOMIG 2.5MG TABS (MIGRAINE)
- PARAMAX
- ZOMIG 5MG NASAL SPRAY
- DISPERSIBLE CO-CODAPRIN TABLETS BP 8/400MG
- PENTAZOCINE TABLETS BP 25MG
- CO-CODAMOL EFF.
- MXL
- LOPRESOR (MIGRAINE)
- PANADOL EXTRA ADVANCE 500 MG/65 MG TABLETS
- DIHYDROCODEINE TABLETS BP 30MG
- NUBAIN
- TRAMACET 37.5 MG/325 MG EFFERVESCENT TABLETS
- SOLPADEINE MAX SOLUBLE TABLETS
- FORTRAL
- MORPHINE SULPHATE SUPPOSITORIES
- OXYNORM 50 MG/ML, SOLUTION FOR INJECTION OR INFUSION
- ZAMADOL SR CAPSULES 50MG, 100MG, 150MG, 200MG
- RELPAX 20MG AND 40MG FILM-COATED TABLETS
- CYCLIMORPH 15 INJECTION
- VEGANIN
- CODIPAR CAPLETS 15/500
- ASPIRIN TABLETS BP 300MG
- TILODOL SR 150 MG PROLONGED-RELEASE TABLETS
- ZYDOL SR 50 MG TABLETS
- DUROGESIC DTRANS 12/25/50/75/100 MCG/HR TRANSDERMAL PATCH
- ZOMIG RAPIMELT 5 MG ORODISPERSIBLE TABLETS
- ZAMADOL CAPSULES 50 MG
- ELLIMANS UNIVERSAL MUSCLE RUB LOTION
- DHC CONTINUS PROLONGED RELEASE TABLETS 60MG, 90MG AND 120 MG
- ALVEDON SUPPOSITORIES 60, 125, 250 MG
- SANOMIGRAN
- CLOTAM RAPID
- DROMADOL SR
- PARACODOL TABLETS
- DEXTROPROPOXYPHENE (GENERIC)
- DIFLUNISAL (ANALGESIA) (GENERIC)
- IMIGRAN RADIS TABLETS (50MG AND 100MG)
- DEPODUR (EXTENDED RELEASE MORPHINE SULFATE)
- CALPOL INFANT SUGAR FREE COLOUR FREE 120 MG/5 ML ORAL SUSPENSION
- BUTRANS 5, 10 AND 20UG/H TRANSDERMAL PATCH
- OXYNORM 5, 10, 20 MG
- FLURBIPROFEN
- MIGRANAL
- ZOMORPH
- PALEXIA 50 MG FILM-COATED TABLETS
- SEVREDOL TABLETS 10MG, 20MG AND 50MG
- OXYCONTIN 15 MG, 30 MG, 60 MG, 120MG PROLONGED RELEASE TABLETS
Advert for Healthcare Professionals only